Whats new
Whats new.
Maxim - An Imbalance in the 1L H&N Control Arm Data but the Overall Efti + Keytruda Combo is Positive and Consistent; Reiterate Buy, $12 PT (Analyst: Jason McCarthy, Ph.D.)
June 27th 2024
For a copy of this analyst report please contact your Maxim advisor